Cho Pharma Inc.   Report issue

For profit Phase 2
Founded: Taipei Taiwan (2013)
Status: Defunct (2023)

Organization Overview

First Clinical Trial
2018
NCT03221348
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cho Pharma Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

cho-h01 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Follicular (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1